Provide an overview of how genomics and mendelian randomization can be used to identify drug targets to prevent cardiovascular disease, using aortic valve disease as an example, and then discuss the design of proof-of-concept randomized trials that can provide biological confirmation of drugdrug target combinations.
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SYNOPSIS:
Provide an overview of how genomics and mendelian randomization can be used to identify drug targets to prevent cardiovascular disease, using aortic valve disease as an example, and then discuss the design of proof-of-concept randomized trials that can provide biological confirmation of drugdrug target combinations.
OBJECTIVES:
1. To describe how genomics and Mendelian Randomization can provide evidence in support of preventive interventions and therapeutic targets 2. To review the role of lipoprotein(a) and other lipoproteins in the development of valve disease 3. To review how small proof-of-principle randomized trials using biological outcomes can support the development of novel therapeutic targets
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